Descripción de la empresa
Cosmos Health Inc. operates as a specialized entity within the healthcare sector, specifically focusing on the medical distribution industry, where it manufactures, develops, and trades branded nutraceutical products across a diverse international footprint that includes Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company's portfolio encompasses a comprehensive range of offerings such as prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, and cosmetics, positioning it as a multi-channel distributor with significant geographic reach. In terms of scale, the company carries a market capitalization of $11.14M and reported annual revenue of $59.79M over the trailing twelve months, supported by a workforce of 149 employees. These valuation and revenue metrics indicate a small-cap status relative to major pharmaceutical peers, suggesting a business model that relies on high operational leverage and potentially higher volatility due to its exposure to regulatory shifts in multiple European and Middle Eastern jurisdictions. The combination of a modest market cap with nearly $60 million in annual revenue highlights a company that generates substantial top-line activity while maintaining a lean organizational structure, a characteristic often found in niche distribution firms that face margin compression pressures typical of their sector.
Salud financiera
The company reported a revenue of $59.79M for the trailing twelve months, yet this top-line performance is offset by a significant net income loss of $-18,542,138 and an EBITDA of $-12,621,250, revealing a cost structure where operating expenses substantially exceed gross profits. The generation of negative free cash flow, quantified at $-5,310,300, indicates that the company is currently burning cash rather than generating liquidity, which limits its financial flexibility for capital expenditures, strategic acquisitions, or organic expansion without external financing. Margin analysis shows a gross margin of 11.4%, an operating margin of -10.6%, and a profit margin of -31.0%, where the disparity between the positive gross margin and deeply negative operating and profit margins points to high fixed costs, aggressive selling expenses, or significant non-operating charges eroding overall profitability. On the balance sheet, the company holds cash totaling $922,619 against a total debt load of $21.07M, resulting in a debt-to-equity ratio of 91.08% which signifies a highly leveraged financial position rather than a conservative one. The current ratio stands at 0.99, indicating that the company's current assets barely cover its current liabilities, suggesting a precarious short-term liquidity situation where working capital management is critical to avoiding insolvency. Return on equity is recorded at -63.8% and return on assets at -13.0%, metrics that reveal a complete lack of management effectiveness in generating value from shareholder capital and operational assets, as both return metrics are deeply negative.
Evaluación de valoración
Valuation metrics for Cosmos Health Inc. present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of earnings, while the forward P/E is calculated at -2.71, implying that the market prices the stock based on anticipated future earnings recovery rather than current profitability. The price-to-book ratio is 0.41, indicating that the market values the company at less than half of its book value, which typically suggests the market perceives significant underlying asset impairments, brand dilution, or severe operational inefficiencies. Alternative valuation measures such as the price-to-sales ratio of 0.19 and an EV/EBITDA of -2.42 further underscore the distressed nature of the valuation, as investors are paying a negligible multiple of revenue for a company currently unable to service its debt or generate positive cash flow. Regarding trading ranges, the stock has a 52-week high of $1.32 and a 52-week low of $0.28, meaning the current price sits at the lower end of this spectrum, reflecting the market's skepticism regarding the company's ability to reverse its financial trajectory in the near term. The beta value is 4.46, a figure that indicates the stock price is more than four times as volatile as the broader market, exposing investors to extreme price swings that are characteristic of small-cap biotech or distribution firms facing regulatory or operational headwinds.
Growth & Income
The company demonstrated a revenue growth rate of 37.9% year-over-year, while earnings growth is listed as N/A due to the persistent net losses, implying that top-line expansion is not yet translating into bottom-line profitability and that the company is still in a growth phase that requires heavy reinvestment. As a non-dividend payer, the company does not distribute a dividend yield or operate with a payout ratio, instead choosing to reinvest its limited earnings and cash reserves into business growth initiatives rather than providing income to shareholders. The overall growth and income profile is defined by aggressive revenue expansion that has not yet stabilized into sustainable profitability, coupled with a complete absence of dividend income, which positions the stock strictly as a speculative growth play rather than an income investment. This profile suggests that any future value appreciation for Cosmos Health Inc. will depend entirely on the company's ability to convert its high revenue growth into positive net income and free cash flow within the foreseeable future.